



Pharma Services

23rd May 2007

MA(IMP) for MDS Pharma Services

A revised Manufacturer's Authorisation, dated 26/1/2007 was received by MDS Pharma Services at the beginning of May 2007.

On reviewing this revision it a number of discrepancies were noticed and [REDACTED] at the MHRA was contacted by the Site Director, [REDACTED], by telephone on Monday 14th May 2007 at 11.30 a.m. to discuss how this could be rectified.

[REDACTED] was asked to send a copy of the previous and most recent licences so that the amendments could be made. This was done on Monday 14th May.

Since we had had no response, [REDACTED] was contacted again by [REDACTED] on Wednesday 23rd May 2007 at 10.30 a.m. [REDACTED] confirmed that she had received the documents but now requested that we make the actual changes required manually on the document and resubmit this by email. This has been completed and [REDACTED] has stated that an amended copy will be available by the end of this week.

In my position as Consultant QP, I can confirm that MDS Pharma Services is legally authorised by the MHRA to dose prepare for the A8361011 study.

[REDACTED]

Consultant QP